Studies in LCH have shown BRAF mutations in the peripheral blood and CD34 + HSPCs of high-risk multisystem disease patients, while the presence of a BRAF mutation only in lesional tissue correlated with low-risk disease with a possible increased risk of recurrence [31, 32]. This evidence concerns the gene BRAF and Langerhans cell histiocytosis.